Glenmark launches Adapalene Gel USP 0.1% in new pump packs in US
Glenmark’s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin Gel, 0.1%
Glenmark Therapeutics Inc., USA (Glenmark) has announced the launch of Adapalene Gel USP, 0.1 per cent (OTC) in new pump packs in the US.
Glenmark’s Adapalene Gel USP, 0.1 per cent can be compared to the active ingredient of Differin Gel, 0.1 per cent.
According to Nielsen syndicated data for the latest 52-week period ending September 5, 2026, the Differin Gel, 0.1 per cent (OTC) market achieved annual sales of approximately $45.8 million*.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, “The introduction of Adapalene Gel USP, 0.1 per cent (OTC) in a new pump pack enhances consumer experience by offering a convenient and easy to use dispensing option while further strengthening our growing U.S. dermatology portfolio. This launch reflects our commitment to delivering high-quality and affordable healthcare solutions that meet evolving consumer needs.”
*Nielsen® NIQ Discover; Syndicated Data for Period Ending September 5, 2026